By Matt Grossman

 

Bristol Myers Squibb Co.'s deucravacitinib drug for plaque psoriasis achieved positive results in a pair of Phase 3 trials, the drug maker said Friday.

In the studies, adults with moderate to severe plaque psoriasis took 6 mg of the oral drug once a day. In both trials, more than 50% of patients achieved at least a 75% improvement from baseline on a psoriasis metric after 16 weeks, compared with under 15% among patients who got a placebo and 35% to 40% among patients who took Otezla, another psoriasis drug. The share of patients with a positive response improved after eight more weeks, and most of those patients maintained their positive response in the 52nd week of treatment.

In the studies, deucravacitinib also performed better than placebo and Otezla in helping patients achieve sPGA 0/1 response, another psoriasis metric based on a physician's assessment.

The drug was well tolerated, Bristol added.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

April 23, 2021 10:35 ET (14:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.